Live Breaking News & Updates on Fibrogen Inc|Page 14

Stay updated with breaking news from Fibrogen inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David Delucia , Michael Szumeraexternal Communications , Drug Administration , Fibrogen Inc , Exchange Commission , North Star Ambulatory Assessment , Thane Wettig , Interim Chief Executive Officer , Duchenne Muscular Dystrophy , Orphan Drug Designation , Fast Track , Rare Pediatric Disease Designation , Looking Statements This , Annual Report , Quarterly Report , Michael Szumeraexternal ,

FibroGen (FGEN) Announces Topline Results from LELANTOS-2

FibroGen (FGEN) Announces Topline Results from LELANTOS-2
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David Delucia , Michael Szumeraexternal Communications , Fibrogen Inc , Exchange Commission , Drug Administration , North Star Ambulatory Assessment , Thane Wettig , Interim Chief Executive Officer , About Duchenne Muscular Dystrophy , Orphan Drug Designation , Fast Track , Rare Pediatric Disease Designation , Looking Statements This , Annual Report , Quarterly Report , Michael Szumeraexternal ,

After-hours movers: Ambarella, HP fall following results and outlook

After-hours movers: Ambarella, HP fall following results and outlook
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Fibrogen Inc , Hp Inc , After Hours Stock Movers , North Star Ambulatory Assessment ,

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

David Delucia , Michael Szumera , Fibrogen Inc , Exchange Commission , Drug Administration , Gen Announces Topline Results , Ambulatory Duchenne Muscular , North Star Ambulatory Assessment , Thane Wettig , Interim Chief Executive Officer , About Duchenne Muscular Dystrophy , Orphan Drug Designation , Fast Track , Rare Pediatric Disease Designation , Annual Report , Quarterly Report ,

Capula Management Ltd Invests $439,000 in FibroGen, Inc. (NASDAQ:FGEN)

Capula Management Ltd purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 23,520 shares of the biopharmaceutical company’s stock, valued at approximately $439,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes […] ....

United States , Benjamin Cravatt , Jamesa Schoeneck , Raymond James , William Blair , Stifel Nicolaus , Fibrogen Inc , Securities Exchange Commission , Pricet Rowe Associates Inc , Hermes Inc , Norges Bank , Holdings Channel , Capula Management Ltd , Free Report , Pictet Asset Management , Asset Management , Director Benjamin Cravatt , Exchange Commission , Director James , Visit Holdingschannel , Fibrogen Daily , Nasdaq Fgen , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,